Suppr超能文献

铁生物可吸收支架在依赖导管的肺循环新生儿中的可行性、安全性和有效性。

Feasibility, safety, and efficacy of iron bioresorbable scaffold in neonates with duct-dependent pulmonary circulation.

作者信息

Mood Marhisham Che, Niazy Khalil Ahmad, Alwi Mazeni, Samion Hasri, Tiong Koh Ghee, Sivalingam Sivakumar, Zhang Deyuan

机构信息

Paediatric and Congenital Heart Centre, Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia.

Department of Paediatric, Hospital Serdang, Selangor, Malaysia.

出版信息

Ann Pediatr Cardiol. 2022 Mar-Apr;15(2):147-153. doi: 10.4103/apc.apc_187_21. Epub 2022 Aug 19.

Abstract

INTRODUCTION

Bioresorbable stent has the theoretical advantage in the pediatric age group; however, experience in the literature is very limited.

OBJECTIVES

This pilot study sought to evaluate the feasibility, safety, and performance of iron bioresorbable scaffold (IBS Angel™) as short-term palliation in lesions with noncomplex patent ductus arteriosus (PDA).

MATERIALS AND METHODS

Nine neonates with duct dependent but dual-source pulmonary blood flow (PBF) were included. Major stent-related complications, in-hospital course, stent patency up to 6 months, and unplanned re-interventions were studied, as well the percentage of stent material resorbed in patients in whom the stents were explanted at the surgery.

RESULTS

IBS Angel™ was successfully implanted in all nine patients (mean weight range 3.4 ± 0.4 kg). Six were pulmonary atresia with an intact ventricular septum and 1 critical pulmonary stenosis patients where PDA stenting was done together or after balloon dilation. The mean procedure and fluoroscopy times were 89 ± 39 min and 16.3 ± 6.9 min, respectively. There were no major complications such as stent thrombosis or embolization and there were no in-hospital deaths. Post procedure overshunting and prolonged ventilatory support was a prominent feature. The median ventilation days was 3 (1-11 days). One patient died after 1 month due to respiratory syncytial virus pneumonia at the referring hospital. At 6 months follow-up, four had patent stents and four had blocked or restrictive stent flow. One patient received re-stenting at 4 months for restrictive stent flow. In three patients where microcomputed tomography of explanted stent was available, resorption of iron was 15% at 6 months and >65% at 16 months.

CONCLUSIONS

Ductal stenting with IBS Angel™ is feasible and safe in selected patients. Because of early luminal loss, its use may be recommended for lesions with dual-source PBF with noncomplex PDA morphology that requires a short duration of palliation.

摘要

引言

生物可吸收支架在儿科年龄组具有理论优势;然而,文献中的经验非常有限。

目的

本前瞻性研究旨在评估铁生物可吸收支架(IBS Angel™)作为非复杂性动脉导管未闭(PDA)病变短期姑息治疗的可行性、安全性和性能。

材料与方法

纳入9例依赖导管但具有双源肺血流(PBF)的新生儿。研究主要的支架相关并发症、住院过程、6个月内的支架通畅情况以及计划外再次干预,同时研究手术取出支架的患者中支架材料的吸收百分比。

结果

IBS Angel™成功植入所有9例患者(平均体重范围3.4±0.4kg)。6例为室间隔完整的肺动脉闭锁,1例为重度肺动脉狭窄患者,PDA支架置入与球囊扩张同时或之后进行。平均手术时间和透视时间分别为89±39分钟和16.3±6.9分钟。未发生支架血栓形成或栓塞等主要并发症,且无住院死亡病例。术后过度分流和延长通气支持是突出特征。通气天数中位数为3天(1 - 11天)。1例患者在转诊医院因呼吸道合胞病毒肺炎于1个月后死亡。在6个月随访时,4例支架通畅,4例支架血流受阻或受限。1例患者因支架血流受限在4个月时接受了再次支架置入。在3例可获得取出支架的微型计算机断层扫描的患者中,6个月时铁的吸收率为15%,16个月时>65%。

结论

对于选定患者,使用IBS Angel™进行导管支架置入是可行且安全的。由于早期管腔狭窄,对于具有双源PBF且PDA形态不复杂、需要短期姑息治疗的病变,可能推荐使用该支架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5616/9564399/d0ad57ee1975/APC-15-147-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验